Mitsubishi UFJ Trust & Banking Corp Increases Holdings in Organon & Co. (NYSE:OGN)

Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of Organon & Co. (NYSE:OGN) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 578,683 shares of the company’s stock after purchasing an additional 47,176 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.22% of Organon & Co. worth $8,634,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Horizon Bancorp Inc. IN boosted its stake in Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the period. Millstone Evans Group LLC bought a new position in shares of Organon & Co. during the fourth quarter worth $29,000. Larson Financial Group LLC boosted its position in shares of Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after acquiring an additional 1,734 shares during the last quarter. Riverview Trust Co grew its stake in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after acquiring an additional 1,324 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 0.3 %

Shares of NYSE OGN opened at $14.52 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The firm’s 50-day moving average price is $15.33 and its 200-day moving average price is $16.24. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of 4.36, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, equities research analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.72%. Organon & Co.’s dividend payout ratio is presently 33.63%.

Analysts Set New Price Targets

Several research firms have commented on OGN. Morgan Stanley dropped their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays reduced their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Organon & Co. presently has an average rating of “Hold” and an average price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.